7,541.40

-38.67

-0.51%

51,983.98

+213.67

+0.41%

25,164.32

-272.68

-1.07%

2,805.88

-5.97

-0.21%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.90%

3,956.40

+57.50

+1.47%

76,790.17

-982.89

-1.26%

Crude Oil Dec 26

96.04

-8.08

-7.76%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Nasdaq Real Time Price USD

Liminatus Pharma, Inc. (LIMN)

2.5200 -0.2300 (-8.36%)

At close: 4:00:00 PM EST

2.5100 -0.0100 (-0.40%)

After hours: 4:15:07 PM EST

Loading Chart for LIMN

Chart Range Bar

Interval:

In partnership with ChartIQ

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock

Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds

Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds

Liminatus Pharma Announces Nasdaq Delisting Notification

Liminatus Pharma Announces Nasdaq Delisting Notification

Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline

Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline

BC-Most Active Stocks

BC-Most Active Stocks

Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody

Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody

BC-Most Active Stocks

BC-Most Active Stocks

BC-Most Active Stocks

BC-Most Active Stocks

Mobilize your Website

View Site in Mobile | Classic

Share by: